SCHEMBL2209493

SCHEMBL2209493

CCCN1CCCC(c2ccc(Nc3nc(Nc4ccccc4C(=O)NC)c4ccnc-4[nH]3)c(OC)c2)C1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IGF1R P08069 4/20 0.48
▸ ZAP70 P43403 1/20 0.43
▸ KDM2B Q8NHM5 2/20 0.41
▸ MET P08581 3/20 0.41
▸ ALK Q9UM73 3/20 0.41
▸ PTK2 Q05397 7/20 0.40
▸ CDC7 O00311 1/20 0.40
▸ PLK4 O00444 1/20 0.40
▸ CHEK1 O14757 1/20 0.40
▸ AURKA O14965 1/20 0.40
▸ DCLK1 O15075 1/20 0.40
▸ PDPK1 O15530 1/20 0.40
▸ DAPK3 O43293 1/20 0.40
▸ DYRK3 O43781 1/20 0.40
▸ JAK2 O60674 1/20 0.40
▸ PRKD3 O94806 1/20 0.40
▸ PAK4 O96013 1/20 0.40
▸ CHEK2 O96017 1/20 0.40
▸ EGFR P00533 1/20 0.40
▸ ERBB2 P04626 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2204780 0.93 IGF1R (0.56) IGF1RZAP70KDM2BALKPTK2
SCHEMBL2207800 0.92 ALK (0.46) IGF1RZAP70METALKPTK2
SCHEMBL2205730 0.87 IGF1R (0.52) IGF1RALKMAPK8CAMK2DGRK2
Gsk-1173862A SCHEMBL2206397 0.85 IGF1R (0.68) IGF1RPTK2CSF1RGRK2GRK5
SCHEMBL2204456 0.85 IGF1R (0.46) IGF1RZAP70ALKPTK2INSR
SCHEMBL2203440 0.82 IGF1R (0.57) IGF1RMETALKPTK2CDC7
SCHEMBL12429392 0.80 IGF1R (0.74) IGF1RALKPTK2INSRMAPK8
SCHEMBL2206560 0.78 IGF1R (0.51) IGF1RTNK2GRK2GRK5
SCHEMBL2206405 0.78 IGF1R (0.51) IGF1RALKPTK2EGFRINSR
SCHEMBL2206378 0.78 IGF1R (0.54) IGF1RZAP70METALKPTK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188292-B1 2- [ (2-{PHENYLAMINO}-1H-PYRROLO [2, 3-D]PYRIMIDIN-4-YL) AMINO]BENZAMIDE DERIVATIVES AS IGF-1R INHIBITORS FOR THE TREATMENT OF CANCER GLAXOSMITHKLINE IP DEV LTD (GB) 2013-05-29 — — EP disclosed
US-7981903-B2 2-[2-{phenylamino}-1H-pyrrolo[2,3-D]pyrimidin-4-yl)amino] benzamide derivatives as IGF-1R inhibitors for the treatment of cancer GLAXOSMITHKLINE LLC (US) 2011-07-19 — — US disclosed
US-20100204196-A1 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer GLAXOSMITHKLINE LLC 2010-08-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100204196-A1 2-[2--1H-Pyrrolo[2,3-D]Pyrimidin-4-YL)Amino] Benzamide Derivatives As IGF-1R Inhibitors For The Treatment Of Cancer IGF1R, IGFBP2, IGFBP1 IGF1R 1/4885ZAP70 2597/4885KDM2B 1534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback